Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care

Neuropediatrics 2019; 50(S 02): S1-S55
DOI: 10.1055/s-0039-1698172

Oral Presentations

Neuromuscular Diseases and Varia

Georg Thieme Verlag KG Stuttgart · New York

André Müller-York

¹Sarepta Therapeutics Germany GmbH, Medical Director, Berlin, Germany

,

Joel Iff

²Sarepta Therapeutics, Inc., HEOR and Market Access, Cambridge, Massachusetts, United States

,

Charles Gerrits

²Sarepta Therapeutics, Inc., HEOR and Market Access, Cambridge, Massachusetts, United States

,

Gautam Sajeev

³Analysis Group, Manager, Boston, Massachusetts, United States

,

James Signorovitch

⁴Analysis Group, Managing Principal, Boston, Massachusetts, United States

,

Edward Tuttle

⁵Analysis Group, Managing Principal, Menlo Park, California, United States

,

Erica Birk

⁶Analysis Group, Associate, Menlo Park, California, United States

,

Intekhab Hossain

⁷Analysis Group, Analyst, Boston, Massachusetts, United States

,

Zhiwen Yao

⁸Analysis Group, Senior Analyst, Boston, Massachusetts, United States

,

Courtney Ng

⁹Analysis Group, Senior Analyst, Menlo Park, California, United States

,

Nathalie Goemans

¹⁰Pediatric Neurology Pediatric, University Hospital Leuven, Leuven, Belgium